Suppr超能文献

膀胱小细胞癌保留膀胱治疗后的膀胱内复发:特征、治疗及结果

Intravesical recurrence after bladder sparing treatment of small cell carcinoma of the bladder: Characteristics, treatment, and outcome.

作者信息

van de Kamp Maaike, Meijer Richard, Pos Floris, Kerst Martijn, van Werkhoven Eric, van Rhijn Bas, Horenblas Simon, Bex Axel

机构信息

Department of urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.

Department of urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.

出版信息

Urol Oncol. 2018 Jun;36(6):307.e1-307.e8. doi: 10.1016/j.urolonc.2018.02.015. Epub 2018 Mar 23.

Abstract

INTRODUCTION

Small cell carcinoma of the bladder (SCCB) is a rare and lethal disease. Previously, we and others have reported a bladder sparing strategy with platinum-etoposide-based chemotherapy followed by radiotherapy of the bladder. Little is known on frequency and treatment of intravesical recurrence following this approach. The objective of this study is to describe the incidence of intravesical recurrences and their management.

MATERIALS AND METHODS

Retrospective study including all patients with SCCB treated at a single institution from 1993 until 2016. All patients with limited disease (LD) SCCB who had a bladder sparing approach with sequential chemotherapy and radiotherapy were identified. Intravesical and overall recurrence rate, overall and disease specific survival, salvage treatment options and their results were retrieved.

RESULTS

Of the 110 patients with SCCB (82% male) with a mean age of 65 years and a median follow up of 48 months, 89 patients (81%) had LD-SCCB. Of these, 65 were treated with chemotherapy and radiotherapy, with a median overall recurrence free survival of 22 months (CI: 14-30). Of 65 patients, 23 (35%) progressed to distant metastasis without intravesical recurrence after a median of 9 months (CI: 8-11), whereas 14 patients (22%) developed isolated intravesical recurrence at a median of 24 months (CI: 14-34). Local recurrence contained SCCB, urothelial carcinoma, and carcinoma in situ and was treated with various local salvage treatments including TURB, cystectomy, neoadjuvant chemotherapy, and BCG. Following salvage treatment a complete response was seen in 64%. Median overall survival for intravesical vs. systemic recurrence was different, with 28 (CI: 9-47) and 8 (CI: 5-11) months, respectively (P<0.001).

CONCLUSION

SCCB is a serious potentially lethal disease. Even in patients with LD-SCCB a high percentage rapidly develops systemic disease. This suggests that systemic therapy is more important than the type of local treatment to control the disease but small sample sizes limit the ability to distinguish between different treatment options in this study. A bladder sparing approach can be a reasonable alternative to major surgery. However, in those surviving long enough isolated intravesical recurrence occurs even after many years. Our results indicate that long term follow up is required because salvage therapy can be successful in the majority of patients.

摘要

引言

膀胱小细胞癌(SCCB)是一种罕见的致命性疾病。此前,我们和其他研究人员报告了一种膀胱保留策略,即采用以铂类-依托泊苷为基础的化疗,随后对膀胱进行放疗。对于采用这种方法后的膀胱内复发频率和治疗情况,人们了解甚少。本研究的目的是描述膀胱内复发的发生率及其处理方法。

材料与方法

一项回顾性研究,纳入了1993年至2016年在单一机构接受治疗的所有SCCB患者。确定了所有采用序贯化疗和放疗的局限性疾病(LD)SCCB患者。收集膀胱内复发率和总复发率、总生存率和疾病特异性生存率、挽救治疗方案及其结果。

结果

110例SCCB患者(82%为男性),平均年龄65岁,中位随访时间48个月,其中89例(81%)为LD-SCCB。其中,65例接受了化疗和放疗,中位无复发生存期为22个月(CI:14 - 30)。65例患者中,23例(35%)在中位9个月(CI:8 - 11)后进展为远处转移,无膀胱内复发,而14例患者(22%)在中位24个月(CI:14 - 34)时出现孤立性膀胱内复发。局部复发包括SCCB、尿路上皮癌和原位癌,并采用了各种局部挽救治疗,包括经尿道膀胱肿瘤切除术(TURB)、膀胱切除术、新辅助化疗和卡介苗(BCG)。挽救治疗后,64%的患者出现完全缓解。膀胱内复发与全身复发的中位总生存期不同,分别为28个月(CI:9 - 47)和8个月(CI:5 - 11)(P< = 0.001)。

结论

SCCB是一种严重的潜在致命性疾病。即使是LD-SCCB患者,也有很高比例会迅速发展为全身性疾病。这表明,控制疾病方面,全身治疗比局部治疗类型更为重要,但本研究样本量较小,限制了区分不同治疗方案的能力。膀胱保留方法可以是大手术的合理替代方案。然而,在那些存活时间足够长的患者中,即使多年后也会出现孤立性膀胱内复发。我们的结果表明,需要进行长期随访,因为挽救治疗在大多数患者中可能会成功。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验